These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 31039062)

  • 1. Quantifying Unmet Need in Statin-Treated Hyperlipidemia Patients and the Potential Benefit of Further LDL-C Reduction Through an EHR-Based Retrospective Cohort Study.
    Schleyer T; Hui S; Wang J; Zhang Z; Knapp K; Baker J; Chase M; Boggs R; Simpson RJ
    J Manag Care Spec Pharm; 2019 May; 25(5):544-554. PubMed ID: 31039062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
    Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
    JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
    J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimated burden of cardiovascular disease and value-based price range for evolocumab in a high-risk, secondary-prevention population in the US payer context.
    Toth PP; Danese M; Villa G; Qian Y; Beaubrun A; Lira A; Jansen JP
    J Med Econ; 2017 Jun; 20(6):555-564. PubMed ID: 28097904
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of a Markov model analysis to assess the cost-effectiveness of statin therapy for the primary prevention of cardiovascular disease in Korea: the Korean Individual-Microsimulation Model for Cardiovascular Health Interventions.
    Kang HY; Ko SK; Liew D
    Clin Ther; 2009 Dec; 31(12):2919-30; discussion 2916-8. PubMed ID: 20110032
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost Effectiveness of Achieving Targets of Low-Density Lipoprotein Particle Number Versus Low-Density Lipoprotein Cholesterol Level.
    Grabner M; Winegar DA; Punekar RS; Quimbo RA; Cziraky MJ; Cromwell WC
    Am J Cardiol; 2017 Feb; 119(3):404-409. PubMed ID: 27887691
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of the Million Hearts Cardiovascular Disease Risk Reduction Model on Initiating and Intensifying Medications: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Peterson GG; Pu J; Magid DJ; Barterian L; Kranker K; Barna M; Conwell L; Rose A; Blue L; Markovitz A; McCall N; Markovich P
    JAMA Cardiol; 2021 Sep; 6(9):1050-1059. PubMed ID: 34076665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications.
    Axon DR; Vaffis S; Chinthammit C; Lott BE; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
    J Manag Care Spec Pharm; 2020 Dec; 26(12):1529-1537. PubMed ID: 33251989
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intensive statin therapy for Indians: Part-I. Benefits.
    Enas EA; Pazhoor HC; Kuruvila A; Vijayaraghavan K
    Indian Heart J; 2011; 63(3):211-27. PubMed ID: 22734339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
    Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Collins R; Landray MJ; Gray A; Baigent C; Mihaylova B;
    Kidney Int; 2019 Jul; 96(1):170-179. PubMed ID: 31005271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of single agent, uptitration and switching statin treatment strategies for lipid lowering in Sweden.
    Martikainen JA; Soini E; Paulsson T
    Curr Med Res Opin; 2010 Feb; 26(2):389-96. PubMed ID: 20001451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary Prevention Using Cholesterol-Lowering Medications in Patients Meeting New Treatment Guidelines: A Retrospective Cohort Analysis.
    Han X; Fox DS; Chu M; Dougherty JS; McCombs J
    J Manag Care Spec Pharm; 2018 Nov; 24(11):1078-1085. PubMed ID: 30362921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association Between Achieved Low-Density Lipoprotein Levels and Major Adverse Cardiac Events in Patients With Stable Ischemic Heart Disease Taking Statin Treatment.
    Leibowitz M; Karpati T; Cohen-Stavi CJ; Feldman BS; Hoshen M; Bitterman H; Suissa S; Balicer RD
    JAMA Intern Med; 2016 Aug; 176(8):1105-13. PubMed ID: 27322095
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk.
    Soran H; Adam S; Durrington PN
    Atherosclerosis; 2018 Nov; 278():135-142. PubMed ID: 30273874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Associations between statin adherence level, health care costs, and utilization.
    Zhao Y; Zabriski S; Bertram C
    J Manag Care Spec Pharm; 2014 Jul; 20(7):703-13. PubMed ID: 24967523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Long-term Benefit Approach vs Standard Risk-Based Approaches for Statin Eligibility in Primary Prevention.
    Thanassoulis G; Sniderman AD; Pencina MJ
    JAMA Cardiol; 2018 Nov; 3(11):1090-1095. PubMed ID: 30422172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving vascular risk factor targets: a survey of a London general practice.
    Levine AP; Mikhailidis DP; Moross T; Benson K; Gor M
    Angiology; 2008; 59(1):36-46. PubMed ID: 18319220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Residual dyslipidemia according to low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B among statin-treated US adults: National Health and Nutrition Examination Survey 2009-2010.
    Wong ND; Chuang J; Zhao Y; Rosenblit PD
    J Clin Lipidol; 2015; 9(4):525-32. PubMed ID: 26228670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: A real-world evidence study in primary care.
    Guglielmi V; Bellia A; Pecchioli S; Della-Morte D; Parretti D; Cricelli I; Medea G; Sbraccia P; Lauro D; Cricelli C; Lapi F
    Atherosclerosis; 2017 Aug; 263():36-41. PubMed ID: 28599257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.